The Results of Nonoperative Treatment of Craniovertebral Junction Tuberculosis: A Review of Twenty-six Cases
- A Retrospective Analysis of Isoniazid-Monoresistant Tuberculosis: Among Iranian Pulmonary Tuberculosis Patients. Varahram, Mohammad; Javad Nasiri, Mohammad; Farnia, Parissa; Mozafari, Mohadese; Akbar Velayati, Ali // Open Microbiology Journal;2014, Vol. 8, p1
Background and objectives: Isoniazid (INH) is one of the most potent anti-tuberculosis (TB) drugs. The spread and transmission of INH-resistant bacilli are likely to pose a significant problem for National TB control Program (NTP). In this study, we aimed to determine the trend of...
- Endobronchial tuberculosis: Clinical and bronchoscopic features. Popevic, Spasoje; Markovic-Denic, Ljiljana; Skodric-Trifunovic, Vesna // HealthMed;2013, Vol. 7 Issue 2, p593
The aim: To determine the clinical and bronchoscopic features of EBTB in Serbia in eight-year period. Methods: Retrospective clinical study was conducted at the Institute for Lung Diseases and Tuberculosis, Clinical Center of Serbia. In the period from 01/02/1999. to 01/12/2007. all cases of...
- Early descriptions of Grisel's syndrome. Golzari, Samad; Ghabili, Kamyar; Sajadi, Mohammad; Aslanabadi, Saeid // Child's Nervous System;Mar2013, Vol. 29 Issue 3, p359
A letter to the editor is presented in response to the article "Grisel's syndrome: a comprehensive review with focus on pathogenesis, natural history, and current treatment options," by S. Osiro, K. J. Tiwari, P. Matusz, J. Gielecki, R. S. Tubbs, and M. Loukas.
- Combination TB drug approved. // FDA Consumer;Sep94, Vol. 28 Issue 7, p2
Comments on approval by the Food and Drug Administration (FDA) of Rifater, a product that combines three existing tuberculosis drugs into a single tablet. Why this fixed-dose product was developed.
- High prevalence of resistance to second-line anti-TB drugs. // Reactions Weekly;9/8/2012, Issue 1418, p4
The article reports on the Preserving Effective TB Treatment Study (PETTS) which reveals that the prevalence of resistance to second-line antituberculosis drugs is high.
- Are free anti-tuberculosis drugs enough? An empirical study from three cities in China. Shanquan Chen; Hui Zhang; Yao Pan; Qian Long; Li Xiang; Lan Yao; Lucas, Henry // Infectious Diseases of Poverty;10/28/2015, Vol. 4, p1
Background: Tuberculosis (TB) patients in China still face a number of barriers in seeking diagnosis and treatment. There is evidence that the economic burden on TB patients and their households discourages treatment compliance. Methods: A cross-sectional study was conducted in three cities of...
- In vivo veritas: The search for TB drug targets goes live. McKinney, John D. // Nature Medicine;Dec2000, Vol. 6 Issue 12, p1330
The term 'microbial persistence' describes a phenomenon whereby microorganisms which are drug-susceptible when tested outside the body are nevertheless capable of surviving within the body despite intensive therapy with the appropriate antimicrobial drug. In clinical practice this phenomenon...
- Ethambutol/isoniazid/pyrazinamide/rifampicin. // Reactions Weekly;5/5/2012, Issue 1400, p20
The article describes the case of a patient who developed paradoxical worsening of cutaneous lesions after receiving antitubercular therapy for miliary tuberculosis.
- Update on the Treatment of Tuberculosis. Inge, Lisa D.; Wilson, John W. // American Family Physician;8/15/2008, Vol. 78 Issue 4, p457
Approximately one third of the world's population, including more than 11 million persons in the United States, is latently infected with Mycobacterium tuberculosis. Although most cases of tuberculosis in the United States occur in foreign-born persons from endemic countries, the prevalence is...